Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma
Lung cancer is the leading cause of cancer-related death worldwide. Recent advances in the management of non-small cell carcinoma are focused on the discovery of targeted therapies and novel immunotherapy strategies for patients with advanced disease. Treatment with anti PD-(L)1 immune checkpoint in...
Main Authors: | Alejandro García, Gonzalo Recondo, Martín Greco, Máximo de la Vega, Florencia Perazzo, Alejandra Avagnina, Valeria Denninghoff |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844020309610 |
Similar Items
-
Immune determinants of Barrett’s progression to esophageal adenocarcinoma
by: Kiran H. Lagisetty, et al.
Published: (2021-01-01) -
CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation
by: Kathryn E. Beckermann, et al.
Published: (2020-08-01) -
Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy
by: Robainas M, et al.
Published: (2017-03-01) -
Inhibitors of the PD1/PD-L1 interaction: missteps, mechanisms and mysteries
by: Hanley, Ronan
Published: (2018) -
The PD1: PD-L1/2 pathway from discovery to clinical implementation
by: Kankana Bardhan, et al.
Published: (2016-12-01)